Novel Targeting of Transcription and Metabolism in Glioblastoma.

CONCLUSIONS: TG02 inhibits multiple survival mechanisms and synergistically decreases energy production with temozolomide, representing a promising therapeutic strategy in GBM, currently under investigation in an ongoing clinical trial.
PMID: 29254993 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 18, 2017 Category: Cancer & Oncology Authors: Su YT, Chen R, Wang H, Song H, Zhang Q, Chen LY, Lappin H, Vasconcelos G, Lita A, Maric D, Li A, Celiku O, Zhang W, Meetze KA, Estok T, Larion M, Abu-Asab M, Zhuang Z, Yang C, Gilbert MR, Wu J Tags: Clin Cancer Res Source Type: research